rss
Ann Rheum Dis 2008;67:296-301 doi:10.1136/ard.2007.076091
  • Extended report

The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis

  1. A P Anandarajah1,
  2. E M Schwarz2,
  3. S Totterman3,
  4. J Monu4,
  5. C Y Feng5,
  6. T Shao6,
  7. S A Haas-Smith6,
  8. C T Ritchlin1
  1. 1
    Department of Allergy, Immunology and Rheumatology, University of Rochester, New York, USA
  2. 2
    Department of Orthopedics, University of Rochester, New York, USA
  3. 3
    Virtual Scopics, Rochester, New York, USA
  4. 4
    Department of Radiology, University of Rochester, New York, USA
  5. 5
    Department of Biostatistics, University of Rochester, New York, USA
  6. 6
    Clinical Immunology Research Center, Allergy, Immunology & Rheumatology Research Division, University of Rochester Medical Center, New York, USA
  1. A P Anandarajah, Clinical Immunology Research Center, 601 Elmwood Avenue, Box 695, Rochester, New York 14642; allen_anandarajah{at}urmc.rochester.edu
  • Accepted 13 October 2007
  • Published Online First 29 October 2007

Abstract

Objective: The frequency of osteoclast precursors (OCPF) and the presence of bone marrow oedema (BMO) are potential response biomarkers in psoriatic arthritis (PsA). Previous studies suggest a central role for tumour necrosis factor (TNF) in the formation of osteoclast precursors. To better understand this association, the effect of etanercept on OCPF and BMO was analysed in PsA patients with erosive arthritis.

Methods: A total of 20 PsA patients with active erosive PsA were enrolled. Etanercept was administered twice weekly for 24 weeks. OCPF was measured and clinical assessments were performed at baseline, 2, 12 and 24 weeks. Gadolinium enhanced MR images were obtained at baseline and 24 weeks.

Results: Significant improvements in joint score (p<0.001), HAQ scores (p<0.001) and SF-36 parameters were observed after 6 months of therapy with etanercept compared to baseline. The median OCPF decreased from 24.5 to 9 (p = 0.04) and to 7 (p = 0.006) after 3 months and 6 months of treatment, respectively. MR images were available for 13 patients. The BMO volume decreased in 47 and increased in 31 sites at 6 months. No correlation was noted between OCPF, BMO and clinical parameters.

Conclusion: The rapid decline in OCPF and overall improvement in BMO after anti-TNFα therapy provides one mechanism to explain the anti-erosive effects of TNF blockade in PsA. Persistence of BMO after etanercept treatment, despite a marked clinical response, was unexpected, and suggests ongoing subchondral inflammation or altered remodelling in PsA bone.

Footnotes

  • Funding: This study was funded by Amgen Inc., Thousand Oaks, California, USA

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. ard.2007.076091v1
    2. 67/3/296 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.